Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort

Adi Lahat, Herma H Fidder, Shomron Ben-Horin, Adi Lahat, Herma H Fidder, Shomron Ben-Horin

Abstract

Background: Following an attack of acute diverticulitis (AD), many patients continue to suffer from a complex of symptoms, titled 'symptomatic uncomplicated diverticular disease (SUDD)'. To date, there is no validated clinical score for standardized assessment of patients with SUDD, thereby hampering the interpretation of observational studies and the conductance of clinical trials.We aimed to develop a validated SUDD clinical score.

Methods: Data from previous prospective study of patients after AD was used to devise the score's first version. Validation was first performed using a focus group of patients after AD SUDD who underwent a structured cognitive personal interview. Thereafter, the diverticular clinical score (DICS) was applied for a second validation cohort. DICS scores of validation cohort were compared with physicians' global assessment for disease severity and inflammatory markers.

Results: In DICS second validation using 48 patients prospectively recruited after AD SUDD, a correlation matrix demonstrated strong correlation between total questionnaire's score and the presence of elevated inflammatory markers (ρ = 0.84). Mean score in patients with elevated inflammatory markers compared with those without inflammation was 17.8 versus 6.2, respectively, p < 0.001. Cronbach's α for measuring internal consistency was 0.91. DICS discriminated accurately between patients with/without active disease, as gauged by the physicians global assessment (area under the curve receiver operating characteristic = 0.989).

Conclusions: Patients suffering from post-AD SUDD exhibit a wide range of symptoms. The newly developed DICS accurately and reproducibly quantitates SUDD-related symptom severity. The DICS may prove useful for monitoring SUDD in clinical practice and in research settings, as well as facilitating patient stratification and therapeutic decisions.

Keywords: acute diverticulitis; clinical score; diverticular disease; symptomatic uncomplicated diverticular disease.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

© The Author(s), 2020.

Figures

Figure 1.
Figure 1.
Sample size graph.
Figure 2.
Figure 2.
Correlation between single questions and total score to disease severity and inflammatory markers.
Figure 3.
Figure 3.
Total score by inflammatory marker elevation.
Figure 4.
Figure 4.
Total score predicting marker elevation.

References

    1. Hughes LE. Postmortem survey of diverticular disease of the colon. Gut 1969; 10: 336–351.
    1. Garcia G. Diverticulitis. In: Blaser MT, Smith DD, Ravdin JI, et al. (eds) Infections of the gastrointestinal tract. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002, pp. 306–316.
    1. Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975; 4: 53–69.
    1. Painter NS, Burkitt DP. Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol 1975; 4: 3–21.
    1. Farrell RJ, Farrell JJ, Morrin MM. Diverticular disease in the elderly. Gastroenterol Clic North Am 2001; 30: 475–496.
    1. Wong WD, Wexner SD, Lowry A, et al. Practice parameters for the treatment of sigmoid diverticulitis- supporting documentation. Dis Colon Rectum 2000; 43: 289–297.
    1. Shahedi K, Fuller G, Bolus R, et al. Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol 2013; 11: 1609–1613.
    1. Kaiser AM, Jiang JK, Lake JP, et al. The management of complicated diverticulitis and the role of computed tomography. Am J Gastroenterol 2005; 100: 910–917.
    1. Daniels L, Ünlü Ç, de Korte N, et al.; Dutch Diverticular Disease (3D) Collaborative Study Group. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. Br J Surg 2017; 104: 52–61.
    1. Cuomo R, Barbara G, Pace F, et al. Italian consensus conference for colonic diverticulosis and diverticular disease. United European Gastroenterol J 2014; 2: 413–442.
    1. Tursi A, Brandimarte G, Di Mario F, et al. International consensus on diverticulosis and diverticular disease. Statements from the 3rd international symposium on diverticular disease. J Gastrointestin Liver Dis 2019; 28(Suppl. 4): 57–65.
    1. Tursi A, Brandimarte G, Elisei W, et al. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009; 24: 49–55.
    1. Tursi A, Elisei W, Brandimarte G, et al. Mucosal tumour necrosis factor α in diverticular disease of the colon is overexpressed with disease severity. Colorectal Dis 2012; 14: e258–e263.
    1. Lahat A, Necula D, Yavzori M, et al. Prolonged recurrent abdominal pain is associated with ongoing underlying mucosal inflammation in patients who had an episode of acute complicated diverticulitis. J Clin Gastroenterol. Epub ahead of print 19 January 2018. DOI: 10.1097/MCG.0000000000000980.
    1. Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther 2011; 33: 902–910.
    1. Kruis W, Meier E, Schumacher M, et al.; German SAG-20 Study Group. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo-controlled study. Aliment Pharmacol Ther 2013; 37: 680–690.
    1. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 2013; 38: 741–751.
    1. Lahner E, Esposito G, Zullo A, et al. High-fiber diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 2012; 18: 5918–5924.
    1. Colecchia A, Vestito A, Pasqui F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007; 13: 264–269.
    1. Campanini A1, De Conto U, Cavasin F, et al. A primary-care interventional model on the diverticular disease: searching for the optimal therapeutic schedule. J Clin Gastroenterol 2016; 50(Suppl. 1): S93–S96.
    1. US Department of Health and Human Services FDA Center for Drug Evaluation and Research; US Department of Health and Human Services FDA Center for Biologics Evaluation and Research and US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4: 79.
    1. Lahat A, Avidan B, Sakhnini E, et al. Acute diverticulitis: a decade of prospective follow-up. J Clin Gastroenterol 2013; 47: 415–419.
    1. Huskisson EC. Measurement of pain. Lancet 1974; 2: 1127–1131.
    1. Bodger K, Ormerod C, Shackcloth D, et al.; IBD Control Collaborative. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut 2014; 63: 1092–1102.
    1. DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007; 45: S12–S21.
    1. Irwin DE, Varni JW, Yeatts K, et al. Cognitive interviewing methodology in the development of a pediatric item bank: a patient reported outcomes measurement information system (PROMIS) study. Health Qual Life Outcomes 2009; 7: 3.
    1. Ambrosetti P, Becker C, Terrier F. Colonic diverticulitis: impact of imaging on surgical management—a prospective study of 542 patients. Eur Radiol 2002; 12: 1145–1149.
    1. Tursi A, Brandimarte G, Giorgetti G, et al. The clinical picture of uncomplicated versus complicated diverticulitis of the colon. Dig Dis Sci 2008; 53: 2474–2479.
    1. Annibale B, Lahner E, Maconi G, et al. Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey. Int J Colorectal Dis 2012; 27: 1151–1159.
    1. Salem TA, Molloy RG, O’Dwyer PJ. Prospective, five years follow-up study of patients with symptomatic uncomplicated diverticular disease. Dis Colon Rectum 2007; 50: 1460–1464.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334.
    1. Bolarinwa OA. Principles and methods of validity and reliability testing of questionnaires used in social and health science researches. Niger Postgrad Med J 2015; 22: 195–201.
    1. Cuomo R, Barbara G, Andreozzi P, et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 2013; 43: 1147–1155.
    1. Bolster LT, Papagrigoriadis S. Diverticular disease has an impact on quality of life – results of a preliminary study. Colorectal Dis 2003; 5: 320–323.
    1. Comparato G, Fanigliulo L, Aragona G, et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis 2007; 25: 252–259.
    1. Spiegel BM, Reid MW, Bolus R, et al. Development and validation of a disease-targeted quality of life instrument for chronic diverticular disease: the DV-QOL. Qual Life Res 2015; 24: 163–179.
    1. Van Dijk ST, Daniels L, de Korte N, et al. Quality of life and persistent symptoms after uncomplicated acute diverticulitis. Dis Colon Rectum 2019; 62: 608–614.
    1. Trepsi E, Colla C, Panizza P, et al. Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results. Minerva Gastroenterol Dietol 1999; 45: 245–252.
    1. Tursi A, Brandimarte G, Giorgetti GM, et al. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312–316.
    1. Comparato G, Fanigliulo L, Aragona G, et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis 2007; 25: 252–259.
    1. Comparato G, Fanigliulo L, Cavallaro LG, et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 2007; 52: 2934–2941.
    1. Smith J, Humes D, Garsed K, et al. OC-119 Mechanistic randomized control trial of mesalazine in symptomatic diverticular disease. Gut 2012; 61: A51–A52.
    1. Kruis W, Meier E, Schumacher M, et al. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon—a placebo-controlled study. Aliment Pharmacol Ther 2013; 37: 680–690.
    1. Parente F, Bargiggia S, Prada A, et al. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration. Int J Colorectal Dis 2013; 28: 1423–1431.
    1. Stollman N, Magowan S, Shanahan F, et al. A randomized controlled study of mesalamine afer acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol 2013; 47: 621–629.
    1. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 2013; 38: 741–751.
    1. Iannone A, Ruospo M, Wong G, et al. Mesalazine for people with diverticular disease: a systematic review of randomized controlled trials. Can J Gastroenterol Hepatol 2018; 2018: 5437135.
    1. Bolkenstein HE, Consten ECJ, van der Palen J, et al. Long-term outcome of surgery versus conservative management for recurrent and ongoing complaints after an episode of diverticulitis. Ann Surg 2019; 269: 612–620.
    1. McHorney CA, Ware JE, Jr, Lu JF, et al. The MOS 36-item short-form health survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40–66.
    1. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-item short form health survey (SF-36): psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–263.
    1. Ware JE. SF-36 health survey. Manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
    1. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal quality of life index: development, validation and application of a new instrument. Br J Surg 1995; 82: 216–222.
    1. EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199–208.
    1. Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; 315: 514.
    1. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology 1976; 70: 439–444.
    1. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med 1987; 317: 1625–1629.
    1. Tursi A, Brandimarte G, Di Mario F, et al. Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. Dig Dis 2015; 33: 68–76.
    1. Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? Qual Life Res 2009; 18: 115–123.
    1. Strate LL, Morris AM. Epidemiology, pathophysiology, and treatment of diverticulitis. Gastroenterology 2019; 156: 1282–1298.
    1. Simpson J, Scholefield JH, Spiller RC. Origin of symptoms in diverticular disease. Br J Surg 2003; 90: 899–908.
    1. Simpson J, Neal KR, Scholefield JH, et al. Patterns of pain in diverticular disease and the influence of acute diverticulitis. Eur J Gastroenterol Hepatol 2003; 15: 1005–1010.
    1. Peery AF, Keku TO, Addamo C, et al. Colonic diverticula are not associated with mucosal inflammation or chronic gastrointestinal symptoms. Clin Gastroenterol Hepatol 2018; 16: 884–889.
    1. Järbrink-Sehgal ME, Rassam L, Jasim A, et al. Diverticulosis, symptoms and colonic inflammation: a population-based colonoscopy study. Am J Gastroenterol 2019; 114: 500–510.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться